Alzheimer's & Dementia

Background: Up to 30% of individuals harboring core Alzheimer's disease (AD) neuropathology, amyloid-beta (Abeta; A) and tau (T)-remain cognitively unimpaired. Objective: We examine whether MRI measures of cerebral blood flow (CBF) and white matter hyperintensities (WMH) differentiate cognitively impaired (AD or mild cognitive impairment (MCI);AD+MCI) from non-demented individuals with (NDAN) and without (Controls) core AD neuropathology. Methods: A retrospective cohort study (2018-2023) using data from The Wisconsin Registry for Alzheimer's Prevention and Wisconsin Alzheimer's Disease Research Center studies employed linear models comparing group differences in regional gray matter (GM) CBF and whole brain WMH volume. Participants (N=500) underwent 3T MRI, amyloid- (11C-Pittsburgh Compound B) and tau- (18F-MK6240) PET, and neuropsychological assessments. We categorized participants based on PET and cognitive status as Controls (n=416; cognitively unimpaired, A-T-), NDAN (n=38; cognitively unimpaired, A+T+), or AD+MCI (n=46; cognitively impaired, A+T+). Results: Participants were 67 years old (mean), 68% female, and 37% APOE 4+. NDAN, like Controls, had significantly higher CBF than AD+MCI in GM regions susceptible to neurofibrillary tangle formation in early AD (frontal and temporal cortices, and limbic regions (ps<0.05)). Largest CBF differences (22-34%) were observed in GM regions that accumulate amyloid early but remain largely tangle-free during early AD progression, namely the occipital and parietal cortices. WMH volume differentiated AD+MCI from Controls (p=0.002) but not NDAN (p=0.16). Conclusion: CBF differentiated NDAN from AD+MCI, highlighting vascular contributions to cognitive resilience. Most pronounced CBF preservation in NDAN was observed in parietal and occipital cortices, regions typically free of tau until late stages of AD progression.

Background: Plasma phosphorylated tau at threonine 217 (p-Tau217) is a leading blood-based biomarker for Alzheimer's disease (AD). Robust analytical characterization on high-throughput platforms is essential for research use and clinical translation. Objective: To evaluate the analytical performance of an automated plasma p-Tau217 immunoassay and characterize its discrimination of PET-defined amyloid status. Methods: We performed analytical validation of the Access Research Use Only (RUO) plasma p-Tau217 immunoassay on the Beckman Coulter DxI 9000 Access Immunoassay Analyzer and evaluated biomarker discrimination of PET-defined amyloid pathology in a subset of the Bio-Hermes-001 cohort spanning the symptomatic cognitive continuum (mild cognitive impairment or mild AD dementia; cognitively unimpaired participants excluded; n = 449). Analytical precision, sensitivity, linearity, specificity, interference, and sample stability were assessed per Clinical and Laboratory Standards Institute guidelines. Discrimination of PET-defined amyloid status was evaluated using receiver operating characteristic curve and indeterminate zone analyses. Results: The assay demonstrated high precision (within-laboratory CV </=7.1%), excellent sensitivity (limit of detection 0.018-0.021 pg/mL), linearity across the analytical measuring range (R-squared > 0.99), strong epitope specificity (</=1.0% cross-reactivity with other tau phosphoisoforms), and minimal interference from over 60 endogenous and exogenous substances. In 449 research participants plasma p-Tau217 showed strong discrimination between amyloid-positive and amyloid-negative groups (AUC 0.881; 95% CI 0.846-0.915). Application of indeterminate zones systematically improved classification metrics at the cost of fewer definitive classifications. Conclusions: These findings support the Access p-Tau217 (RUO) assay as a robust, high-throughput assay for plasma biomarker-based discrimination of PET-defined amyloid pathology in AD applications.

ABSTRACT Importance: The biological mechanisms underlying the associations of social isolation and loneliness with dementia risk are not well understood. Objective: To evaluate the relationship of prospectively measured social isolation and loneliness with AD/ADRD blood-based biomarkers. Design: Observational study using the U.S. Health and Retirement Study (2010-2016). Venous blood draws were conducted in 2016 and AD/ADRD biomarkers were released in 2025. We estimated associations of social isolation and loneliness patterns between 2012 and 2014 with continuous biomarkers using linear regressions, accounting for socio-demographic and health covariates. We evaluated effect modification by sex and APOE {varepsilon}4 carrier status. Setting: Population-based Participants: Community-dwelling HRS participants aged 50 years or older (n = 3862). Exposures: Primary exposures were four-category multi-wave variables of persistent, resolving, new-onset, or no social isolation/loneliness across the two exposure waves. Social isolation was classified as "severe" and "moderate-to-severe" based on a 5-item scale including marital status, household size, proximity to children, religious service attendance, and volunteering. Past-week loneliness was measured with a single-item question (yes/no). Main Outcomes and Measures: Neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and the ratio of amyloid beta 42 to amyloid beta 40 (A{beta}42/40), measured in plasma via a Multiplex Simoa Assay and phosphorylated tau (p-tau181), measured in serum via a Simoa Assay. Results: At the analytic baseline, respondents were a mean age of 64 (9.5) years, 59% female, and 25% APOE {varepsilon}4 carriers. Across the two exposure waves, 4% experienced persistent severe social isolation, 16% experienced persistent moderate-to-severe social isolation, and 8% reported persistent loneliness. Multiple patterns of social isolation (vs. no social isolation) were associated with higher NfL, including persistent severe social isolation ({beta}: 0.31), new-onset moderate-to-severe social isolation ({beta}: 0.14), and resolving moderate-to-severe social isolation ({beta}: 0.20). Persistent severe social isolation was associated with lower GFAP ({beta}: -0.31) while persistent loneliness and, for men, new-onset loneliness were associated with higher GFAP ({beta}_persistent: 0.16; {beta}_(new onset_men): 0.25). New-onset severe social isolation was associated with a lower A{beta}42/40 ratio ({beta}: -0.25) while resolving moderate-to-severe social isolation and, for men, persistent severe social isolation were each associated with higher p-tau181 ({beta}_resolving: 0 .11; {beta}_(persistent_men): 0.41). There was some additional variation by APOE {varepsilon}4 carriership, although selective survival is a concern. Conclusions: Social isolation was associated with elevated blood-based biomarkers of neuronal injury, with variation by patterns of exposure over time. Associations between social isolation and loneliness with biomarkers related to astrocyte damage and Alzheimer's disease were less consistent, and varied in sign and magnitude by exposure and sex.

INTRODUCTION: Characterizing the prognostic utility of blood-based biomarkers for Alzheimer's disease (AD) in predicting longitudinal cognitive trajectories is essential; however, population-based evidence is needed. METHODS: We evaluated plasma phosphorylated tau at threonine 217 (p-tau217) and plasma neurofilament light chain (NfL) in 4,971 dementia-free individuals aged 70 years and older from the population-based Norwegian HUNT study. Predefined cut offs categorized biomarker ranges (p-tau217: low, intermediate, high; NfL: low, high), in addition to continuous biomarker analysis. RESULTS: Adjusted for other risk factors, higher baseline p-tau217 and NfL ranges indicated a significantly increased dementia risk after four years compared to low ranges (intermediate p-tau217: risk ratio [RR] 1.23, 95% CI 1.01-1.50; high p-tau217: RR 2.05, 95% CI 1.73-2.44; high NfL: RR 1.72, 95% CI 1.31-2.27; jointly high p-tau217 and NfL: RR 3.32, 95% CI 2.61-4.23). The estimated cumulative risk of all-cause dementia was 10.6% (95% CI 9.3-12.1) for low p-tau217, 16.9% (95% CI 14.6-19.5) for intermediate p-tau217, 33.0% (95% CI 29.9-36.1) for high p-tau217, 15.7% (95% CI 14.4-17.0) for low NfL, 35.4% (95% CI 30.6-40.5) for high NfL, and 47.8% (95% CI 40.7-55.0) for jointly high p-tau217 and NfL. The association of p-tau217 with incident dementia differed by sex. DISCUSSION: These findings support the use of blood-based biomarkers for population-level dementia risk stratification, underscore the value of combining markers to improve prognostic precision, and can aid clinicians using plasma p-tau217 or NfL in interpreting dementia risk.

Background: Alzheimer's disease (AD) is characterized by amyloid beta and tau accumulation accompanied by altered inflammatory responses. Sex is an important modifier of AD risk and pathology, however, its influence on relationships between peripheral inflammatory markers and cerebrospinal fluid (CSF) AD biomarkers remains unclear. The aim of this study was to determine whether sex modifies peripheral inflammatory biomarker relationships associated with AD pathology and clinical stage. Materials and Methods: Twelve CSF biomarkers and 41 plasma biomarkers spanning AD pathology, neurodegeneration, and inflammation were measured on the Luminex platform in a cross-sectional cohort of 261 participants from the Cleveland Clinic Lou Ruvo Center for Brain Health Biobank. Associations were evaluated in sex-adjusted, sex-interaction, and sex-stratified models, accounting for age, APOE4 carrier status, and diagnosis. Results: Plasma IL-5 was inversely associated with clinical stage, and 10 plasma inflammatory markers, including Flt-3L, MCP-1, soluble TREM2 (sTREM2), TNF, IL-8, IL-5, IL-12P40, IL-1RA, fractalkine, and G-CSF, were inversely associated with the CSF pTau181/A{beta}42 ratio in pooled models adjusted for sex. Although formal biomarker x sex interactions did not survive FDR correction, significant associations between the CSF pTau181/A{beta}42 ratio and plasma MCP-1 and IL-12P40 were observed in females but not males. Discussion: Our findings identify a group of peripheral inflammatory markers associated with AD pathology and suggest that some of these relationships may vary by sex, warranting larger studies to clarify the role of sex in AD pathobiology.

Complement-mediated neuroinflammation has been implicated in Alzheimer's disease (AD), but its role during the pre-symptomatic phase of the disease remains unclear. In the PREVENT-AD cohort of cognitively unimpaired individuals at increased familial risk of AD, we investigated whether CSF complement proteins relate to early AD pathology and synaptic dysfunction, then assessed our results' reproducibility across the clinical AD spectrum. Baseline CSF C1q, C3, C3b, and Factor H were measured in relation to CSF AD biomarkers, synaptic proteins, cognition, MRI volumetry, and amyloid and tau PET. Key findings were then examined in 708 participants from ADNI spanning cognitively normal, mild cognitive impairment (MCI), and dementia stages of AD. In PREVENT-AD, C1q was positively associated with CSF P-tau181, T-tau, and multiple synaptic markers including ADAM23, GAP43, SNAP25, and SYT1. Factor H showed similarly strong positive associations with P-tau181, T-tau, ADAM22, ADAM23, GAP43, and SYT1. By contrast, C3 showed minimal associations, while C3b displayed weaker positive relationships with P-tau181, T-tau, ADAM22, and ADAM23. Complement proteins were not robustly associated with amyloid or tau PET, and only C1q related to lower global cognitive performance. In ADNI, C1q emerged as the most consistent analyte, showing positive associations with tau, neurofilament light, and synaptic markers across all diagnostic groups. C3 exhibited predominantly negative associations, whereas C3b and Factor H showed stage-dependent relationships, particularly with evident neurodegeneration and synaptic injury in symptomatic individuals. These findings identify complement dysregulation, especially involving C1q, as an early correlate of tau-linked synaptic pathology, and support a role for complement activation in the AD molecular cascade.

Service members with traumatic brain injury are at approximately two- to four-fold higher risk of Alzheimer's disease or related dementias than those without such an injury, with risk increasing with injury severity. The amyloid/tau/neurodegeneration biomarker framework treats amyloid, tau, and neurodegeneration as independent axes but omits astroglial injury, despite evidence that reactive astrogliosis (indexed by glial fibrillary acidic protein, GFAP) must be elevated for cognitive decline to occur in amyloid-positive individuals. Total GFAP immunoassays aggregate intact protein with multiple calpain- and caspase-cleaved proteoforms, blurring the biological signal. We compared a calpain-cleaved GFAP neoepitope, the glial fibrillary acidic protein neoepitope (neoGFAP), against total GFAP across the full traumatic brain injury--mild cognitive impairment--Alzheimer's disease continuum in Veterans using a two-stage plasma-to-cerebrospinal-fluid biomarker approach. A plasma triage gate combining phosphorylated tau 217 and amyloid beta 42 was applied to 367 unique subjects; a cerebrospinal-fluid benchmarking cohort of 57 subjects (controls, chronic blast traumatic brain injury, mild cognitive impairment, and Alzheimer's disease) received head-to-head neoGFAP and total GFAP measurement. In the whole benchmarking cohort, neoGFAP discriminated mild cognitive impairment plus Alzheimer's disease from non-Alzheimer subjects with an area under the receiver-operating-characteristic curve of 0.81 versus 0.73 for total GFAP, a trend-level advantage that did not reach nominal significance. Within the gate-positive, amyloid-committed subset of 23 subjects, neoGFAP dominance became significant by McNemar's exact test (six discordant subjects favored neoGFAP, none the reverse). Across diagnostic contrasts, neoGFAP outperformed total GFAP for Alzheimer's disease versus control and, importantly for Veterans, for mild cognitive impairment versus chronic blast-exposed Veterans without cognitive impairment. In chronic blast injury, neoGFAP was paradoxically depleted relative to controls, consistent with tissue sequestration of aggregated proteoform fragments. Unbiased proteomic profiling confirmed coordinated elevation across astrocytic, neuronal, mitochondrial, and microglial compartments. An exploratory subject-level reclassification improved accuracy from 71.1 percent using plasma alone to 79.5 percent with added cerebrospinal-fluid markers and age. In a same-cohort ProQuantum replication (n=57), CSF neoGFAP preserved its discrimination advantage over total GFAP for MCI+AD versus non-AD (AUROC 0.76 vs 0.72; cross-platform Spearman {rho}=0.84), while plasma neoGFAP achieved AUROC 0.90, comparable to pTau217 (0.92) and exceeding A{beta}42/40 (0.84). In this small sample, neoGFAP is a superior proteoform-resolved diagnostic and prognostic biomarker across the continuum and supports adding an astroglial-proteoform axis to amyloid/tau/neurodegeneration biomarker frameworks in high-risk populations.

Introduction. Neuropsychiatric symptoms (NPS), including aggression, psychosis, anxiety, apathy, and depression, affect up to 85% of individuals with Alzheimer's disease (AD) and are among its most disabling and costly manifestations, accelerating cognitive and functional decline, institutionalization, mortality, and healthcare costs. NPS prevalence has largely been characterized using self-reported race. Whether NPS differs across genetically defined ancestry groups and whether self-reported race obscures these differences remains unknown, limiting accurate risk stratification and treatment development. Methods. Using whole-genome sequencing data from 7,118 ADSP participants, we defined three NPS clusters from the NPI-Q: early psychosis (CDR 0.5-1), late psychosis (CDR 2-3), and affective symptoms. Genetic ancestry was inferred by principal component clustering, identifying six groups (EUR, AFR, EAS, SAS, AMR, ADMIXED), and compared with self-reported race/ethnicity. NPS prevalence was compared across genetic ancestry groups and genetic ancestry and self-reported race using Fisher's exact and regression models. Results. Genetic ancestry assignment differed markedly from self-reported race, affecting NPS prevalence estimates. NPS prevalence also differed across ancestry groups; affective symptoms were highest in EAS (90%) and SAS (77%) and lowest in AFR (66%), while psychosis was highest in EAS (74%) and SAS (70%) and lowest in AMR (55%) and EUR (56%), with similar patterns for early and late psychosis. Discussion. Genetically defined ancestry alters NPS prevalence estimates in AD, suggesting that standard race categories obscure population-level disease burden and compromise risk stratification, screening, and trial design. Ancestry-associated differences suggest partially distinct genetic and environmental drivers, underscoring the need to incorporate genetic ancestry into AD research and care.

Background: Epidemiological studies increasingly associate several adult vaccinations with lower risk of Alzheimer disease (AD) and dementia, but the biological mechanisms underlying these observations remain unclear. We investigated whether adult vaccination history is associated with AD-related and immune-related biomarker profiles in cognitively unimpaired individuals at increased familial risk for AD. Methods: This exploratory study included 192 participants from the PREVENT-AD cohort. Adult vaccination and infection histories were collected using a structured questionnaire and examined in relation to plasma and cerebrospinal fluid (CSF) biomarkers. Adjusted regression models evaluated individual vaccine exposures, vaccination-profile breadth, broader proteomic signatures, CSF biomarkers, viral-history interactions, and psychological symptoms, with false-discovery-rate (FDR) correction applied for multiple testing. Results: Influenza, herpes zoster, pneumococcal, and Td/Tdap vaccination were not associated with FDR-significant differences in the principal plasma amyloid and tau biomarker panel. Hepatitis B vaccination was associated with lower plasma total tau/MAPT, p-tau181, and p-tau231 after correction within the AD biomarker panel, although these findings may reflect residual behavioral or healthcare-related confounding. Greater vaccination-profile breadth was associated with higher plasma NPTX1 (beta = 0.261, p = 0.007, q = 0.049), whereas its nominal association with a lower Amyloid Beta 42/40 ratio did not survive FDR correction. Nominal herpes zoster associations with lower CSF Amyloid Beta 42 and pTau were similarly attenuated after correction. No robust FDR-significant associations emerged from viral-history interaction or psychological symptom analyses. Conclusions: Adult vaccination history was not associated with a broad plasma amyloid or tau signature in this asymptomatic, familial-risk cohort. However, the association between broader vaccination exposure and higher NPTX1 suggests a potentially distinct synaptic-related signal, while the hepatitis B findings identify additional hypothesis-generating tau-related associations. Longitudinal studies incorporating vaccine timing, infection burden, and repeated biomarker measurements are needed to determine whether vaccination influences biological pathways relevant to AD resilience.

The mild cognitive impairment (MCI) continuum represents a critical stage in the Alzheimer's disease (AD), yet much of the genetic determinants underlying early neural dysfunction in AD remain unclear. Electroencephalography (EEG)-derived features as heritable markers of neuronal network activity may provide biologically informative endophenotypes for studying cognitive decline in the MCI. We investigated associations between functional genetic variation and resting-state EEG features in 169 Finnish individuals with symptoms spanning from subjective cognitive decline to MCI. Periodic alpha- and beta-band features and aperiodic spectral parameters were derived from eyes-closed EEG recordings. Genome-wide genotypes were quality-controlled, imputed, functionally annotated (yielding 16,935 gene regions comprising 90,607 functional variants), and associated with latent EEG features using Bayesian reduced rank regression. We integrated the results with neurobiology-related literature review and known AD-associated loci and performed unsupervised clustering of participants based on EEG-associated genetic variation, testing clinical and biomarker differences between clusters. We identified 145 genes associated with periodic EEG features and 39 genes with aperiodic EEG features at P < 0.005, although no associations survived correction for multiple testing. Candidate genes converged on pathways for synaptic transmission, neuronal excitability and neurodevelopment (e.g., RASGEF1C and TREML2 mapped to loci previously associated with AD). The aperiodic-feature candidates were more enriched for neuroinflammatory processes (e.g., C5AR2 within a FinnGen AD-associated region) relative to the periodic-feature candidates which were more frequently involved in intracellular neuronal maintenance and signaling. Unsupervised clustering based on periodic EEG-associated variants delineated participant subgroups differing significantly in plasma p-tau217 concentrations and delayed verbal recall after multiple-testing correction. The top genes contributing to cluster formation included ACAN, INPP5B, CAMKK2, CABIN1 and SPATA13. These findings suggest that periodic and aperiodic EEG features capture partly distinct biological processes within the MCI continuum. The convergence of candidate genes on synaptic, neurodevelopmental and neuroinflammatory pathways, and genetically informed clustering linked to plasma p-tau217 and delayed verbal recall, supports the use of EEG-derived endophenotypes for dissecting heterogeneity in early cognitive decline and AD-related pathology.

BACKGROUND: Chronological age and plasma p-tau217 each predicts cognitive decline, but whether their prognostic associations interact is unclear. In this study, we examined their joint associations in a memory-clinic cohort. METHODS: We included 3,741 participants from the Pittsburgh ADRC, with up to 28 years of follow-up (3.0 [IQR 2.0-6.0]). The primary outcome was increase in Clinical Dementia Rating global score (CDR-GS). Secondary outcomes included clinical-stage progression and longitudinal change in CDR Sum of Boxes. Plasma p-tau217 cut-off value was derived and externally validated in amyloid-beta-PET and autopsy sub-cohorts, respectively. Cox proportional hazards and linear mixed-effects models tested age-by-p-tau217 interactions while repeated cross-validation evaluated prognostic performance. RESULTS: Age and plasma p-tau217 interacted in their associations with CDR-GS progression ({chi}(1)2 = 23.94; p=9.81x10-7). Comparing the oldest displayed age with the youngest reference age, the adjusted hazard ratio (HR) was 4.80 (95% CI 2.74-8.27) in the lowest vs. 1.05 (95% CI 0.69-1.47) in the highest p-tau217 quartile. Older age was associated with clinical progression at low-p-tau217 (HR=1.97; 95% CI 1.58-2.45) but not at high-p-tau217 (HR=1.10; 95% CI 0.95-1.26) concentrations; adjusted 5-year risk differences were 19.3 and 3.3 percentage points, respectively. Adding plasma p-tau217 improved 5-year discrimination most accurately among participants younger than 60 years (AUC 0.66-0.81). DISCUSSION: Prognostic association between age and clinical progression varies by plasma p-tau217 concentration. Age stratifies risk at low plasma p-tau217 levels, whereas elevated p-tau217 identifies higher risk across age groups and attenuates the age-related gradient. These findings support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment.

Background Fluid biomarkers enable the demonstration of the biological effects of novel therapies in Alzheimers disease (AD). However, longitudinal biomarker data are sparse and sample size calculations for fluid biomarkers are often lacking. Here, we provided longitudinal CSF and plasma AD biomarkers measured in samples collected in a placebo arm in a 1.5-year phase 2b trial, allowing us to study natural trajectories, required sample sizes and heterogeneity in early AD clinical trials. Methods We studied individuals from the placebo group (MCI due to AD (n=65) and AD dementia (n=41)) of the T-817MA trial (NCT04191486) with positive CSF AD biomarkers (mean age=69(7) years, Female=63%). Longitudinal biomarker changes in CSF (A{beta}42, A{beta}40, A{beta}42/40, pTau181, pTau217, NFL, tTau, YKL40, NRGN, ABL1, CHIT1, CLEC5A, ITGB2, MMP10, SDC4, SPON2, THBD) and plasma biomarkers (A{beta}42, A{beta}40, A{beta}42/40, pTau181, pTau217, NFL, GFAP) were analyzed with linear mixed-effect models. Required sample size estimates for predefined treatment effects were generated. Lastly, we investigated the influence of between person variability in biomarker change by simulating a randomized clinical trial (1:1) 10000 times, and assessed the group differences at 1.5 years. Findings Fourteen biomarkers changed over time, with the largest annual changes observed for plasma pTau217 (+9.8%), CSF MMP10 (+7.1%), and CSF NFL (+6.9%), and CSF A{beta}40 by (-4.0%), CSF pTau217 (-3.0%), and CSF NRGN (-2.5%). To show a 30% change, similar to biomarker effects of approved AD drugs, almost all markers required less than 45 patients per trial arm. To reach normalized levels, established CSF markers required lower sample sizes than plasma markers. The effects of heterogeneity over time were approximately twice as large in plasma compared to CSF. Interpretation These findings offer insights into the biomarker trajectories and power in early AD, supporting more informed endpoint selection and forming a frame of reference for the interpretation of treatment effects in clinical trials.

Adaptive immune responses may influence vulnerability and resilience in Alzheimers disease (AD), but relevant T-cell states remain unclear. We profiled peripheral immune cells by mass cytometry in 200 participants across distinct age groups, early AD and exceptional old age without dementia, relating immune features to amyloid-{beta} (A{beta}) PET, plasma biomarkers and longitudinal structural and cognitive outcomes. Inducible T-cell co-stimulator (ICOS) expression across CD4 and CD8 memory T-cells was associated with cerebral A{beta} pathology. In mild cognitive impairment (MCI), higher ICOS expression on CD8 memory T-cells strengthened the association between A{beta} load and hippocampal atrophy. A{beta}-derived peptides induced proliferative ICOS+CD25+ memory CD4 and CD8 T-cell responses predominantly in A{beta}-positive participants in an independent cohort. Conversely, higher programmed cell death protein 1 (PD-1) expression on CD8 effector-memory T-cells was associated with attenuated A{beta}-related episodic-memory decline in exceptionally old participants and was higher in stable MCI than in MCI-to-AD converters. These findings identify distinct co-stimulatory and co-inhibitory T-cell correlates of vulnerability and resilience.

Importance: Patients are increasingly learning Alzheimers disease (AD) genetic and biomarker results through electronic health portals. Evaluation of alternative scalable delivery models for return of AD risk information is needed to best support patient understanding and psychological well-being. Objective: To determine whether a patient-centered digital platform is comparable to clinician-mediated telehealth sessions for returning APOE and plasma pTau-217 results on outcomes of knowledge and psychological well-being. Design: The Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results (eSMARTER) study was a noninferiority trial of a patient-centered digital platform compared to clinician-mediated disclosure of APOE genotype and optional pTau-217 disclosure. Setting: Decentralized, fully remote trial enrolled participants in the contiguous United States (U.S.) between October 2024 and February 2025, with follow-up completed in November 2025. Participants: Eligible participants were aged 60-80 and had previously undergone APOE genotyping (without disclosure) via the GeneMatch program, passed psychological screening, had internet access, and were English-speaking. Interventions: Participants were randomized, 2:1, to the eSMARTER digital platform or clinician-mediated disclosure of APOE genotype. Following the 6-month post-APOE assessment, participants were offered optional pTau-217 disclosure via the same randomized modality. Main Outcomes and Measures: Primary outcomes at 1-7 days following APOE disclosure included changes in anxiety, disease-specific distress, and AD-related knowledge within a priori non-inferiority margins. Results: 674 persons (mean [SD] age 68 [4.7] years; 451 [67%] female; mean [SD] telephone MoCA=19 [2]) were eligible and provided demographic information. 651 participants were randomized to clinician-mediated (n=216) or digital disclosure (n=435) and completed APOE disclosure (66 [10%] APOE4 homozygotes, 377 [58%] heterozygotes, 208 [32%] non-carriers). 604 participants completed the study; 500 completed optional pTau-217 disclosure. Baseline characteristics were balanced across groups. At 1-7 days following APOE disclosure, scores on AD-related knowledge, PROMIS Anxiety, and disease-specific distress measures met non-inferiority. Conclusions and Relevance: Disclosure of APOE genotype by the eSMARTER digital platform is non-inferior to clinician-mediated telehealth disclosure. No significant between group differences were found following disclosure of pTau-217 results. Together, these results suggest that this digital platform may provide an evidence-based scalable approach for returning AD genetic and biomarker results.

Structured AbstractO_ST_ABSIntroductionC_ST_ABSBrain glucose hypometabolism is a hallmark of Alzheimers disease (AD), yet conventional [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) analyses have limited sensitivity in preclinical stages. Metabolic brain network approaches may better capture early vulnerability preceding clinical conversion. MethodsCognitively unimpaired individuals (n = 127) from the ADNI cohort with baseline FDG-PET and amyloid (A) and tau (T) status were classified as clinically stable or converters over an average longitudinal follow-up of 5.8 years. Baseline brain FDG uptake patterns were analyzed at the regional, voxel, and network levels across AT profiles. Network density was quantified globally and within functional networks. AD biomarkers and cognitive performance were also examined. ResultsConventional FDG-PET SUVr analyses failed to distinguish cognitively stable individuals from clinical converters at baseline, either at the regional or voxel levels. AT(N) biomarkers and neuropsychological performance likewise did not differ significantly between groups. In contrast, clinical converters exhibited hyperconnected metabolic networks at baseline, including within the default-mode network. These effects were consistent across A-T-, A+T-, and A+T+ groups, with network density higher in clinical converters than in cognitively stable individuals. Conversely, network density among stable individuals declined with AT progression, pointing to divergent network trajectories. DiscussionMetabolic network organization analysis revealed early AD-related vulnerability beyond regional hypometabolism, even before detectable amyloid positivity, and may reflect divergent trajectories of resilience and pathological propagation preceding clinical conversion. By leveraging existing FDG-PET datasets, this framework offers a valuable opportunity to identify individuals at risk of clinical progression at scale.

Amyloid plaques, one of the defining features of Alzheimer's disease, are associated with synapse loss and accumulation of pathological tau in dystrophic neurites and reactive glia in their immediate vicinity. Anti-amyloid-beta; immunotherapies have been shown to effectively remove a large proportion of plaques from the brain, but whether immunotherapies reduce pathological changes around remaining plaques or plaques that emerge after treatment remains unknown. We examined amyloid plaques, synapses, astrocytes, and phosphorylated tau in post-mortem brain tissue from people with Alzheimer's disease who received Amyloid-beta42 immunization in the AN1792 trial (Elan Pharmaceuticals), non-immunized or placebo-treated people with Alzheimer's disease, and neurologically healthy controls. In non-vaccinated individuals, we observe plaque-associated synapse loss, phospho-tau accumulation, and astrogliosis as previously reported. People who received Amyloid-beta42 vaccination had reduced pathology up to 14 years after receiving the vaccine including ameliorated plaque-associated synapse loss, less accumulation of phospho-tau around plaques (AT8 and pTau217), lower levels of astrogliosis, and lower levels of phospho-tau associated with synapses. These data indicate that anti-amyloid active vaccines may have lasting beneficial effects even around remaining plaques or plaques formed after immunization.

INTRODUCTION: Novel capillary-blood collection methods have not yet been evaluated for a wide range of central nervous system (CNS) and neurodegenerative disease-related proteins. Biomarkers of Alzheimer's disease (AD) and related disorders (ADRD) collected from devices like the Tasso+, a minimally invasive upper-arm capillary blood collection device, must be compared to traditional venipuncture to assess for validity. METHODS: Participants underwent blood collection via traditional venipuncture and Tasso+ in a clinical research setting. The Nucleic Acid Linked Immuno-Sandwich Assay (NULISA) CNS panel was used for biomarker quantification in venous and Tasso-derived plasma. RESULTS: Eighty-three participants (age mean{+/-}SD 76.8{+/-}8.2 years, 79.5% cognitively unimpaired) completed blood collection. Little to no correlation was found between venous and Tasso+ plasma for p-tau217, but the correlation was improved by using a brain-derived (BD)-p-tau217/BD-p-tau181 ratio. Extremely strong correlations were found for neurofilament light (NfL) and glial fibrillary acidic protein (GFAP). Among the 131 biomarkers measured, 51 (38.9%) had a Pearson R [&ge;] 0.90; 27 (20.6%) had values between 0.70-0.90; 26 (19.9%) had values between 0.30-0.70; and 27 (20.6%) had values [&le;] 0.30. DISCUSSION: The Tasso+ accurately measures NfL and GFAP, but caution is warranted when measuring other AD/ADRD biomarkers, as agreement with venous plasma appears to be protein or ratio dependent. These results highlight that important biomarker-specific differences must be considered when translating capillary blood collection approaches. They also further support foundations for development of these methods, highlighting both the opportunities and remaining challenges for translating the promise of blood-based biomarkers beyond AD/ADRD specialty clinics and research settings.

Background Blood biomarkers are increasingly used to support the diagnosis and monitoring of neurodegenerative diseases. However, their interpretation is complicated by physiological determinants, including age, sex, body-mass index, and renal function, and by differences in absolute concentrations between analytical methods. We aimed to develop population-based reference equations allowing individualized interpretation of the main blood biomarkers used in neurology. Methods In this cross-sectional study, we analysed plasma samples from cognitively unimpaired participants selected from the French CONSTANCES and Three-City population-based cohorts. Generalized additive models for location, scale, and shape were used to model neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), phosphorylated tau 181 (p-tau181), amyloid-{beta}40, amyloid-{beta}42, and their ratios according to age, sex, body-mass index, and renal function. The resulting equations provided individualized expected concentrations, percentiles, and Z-scores. Previously established disease-specific concentrations were converted into Z-score. Cross-calibration equations were developed for NfL measurements across analytical methods and sample matrices. Findings The final reference populations comprised 5123 participants for amyloid biomarkers and p-tau181 and 5122 for NfL and GFAP; median age was 52.3 years and half were women. Between ages 40 and 80 years, expected NfL and GFAP concentrations increased by an average of 2.6% and 2.2% per year, respectively. Renal function, body-mass index, and sex had additional biomarker-specific effects. Application of the equations to clinical cohorts preserved distinct disease-associated profiles: NfL Z-scores were increased across disorders characterised by neuroaxonal injury, whereas p-tau181 and GFAP showed its greatest increase in Alzheimer disease. NfL cross-calibration equations showed excellent agreement between methods and matrices, with intraclass correlation coefficients greater than 0.90. Interpretation This population-based multibiomarker framework enables blood biomarker concentrations to be interpreted relative to individuals with similar physiological characteristics. Publicly available equations, reference curves, and standardized Z-scores could improve individualized interpretation and comparability across biomarkers, laboratories, and clinical populations.

Background: Late-onset Alzheimer's disease (LOAD) comprises more than 95% of all AD cases. Transgenic, overexpression animal models have off target side effects, do not effectively produce the heterogeneity observed clinically in LOAD patients, and are therefore not best suited for preclinical therapeutic development. The Model Organism Development and Evaluation for Late-onset Alzheimer's Disease (MODEL-AD) Consortium was established to develop novel mouse strains to model human-relevant genetic and environmental risk factors for LOAD. Methylenetetrahydrofolate reductase (MTHFR) is an enzyme in the folate/methionine pathway. Variants in the MTHFR gene, notably 677C>T, are associated with ADRD, and we have previously shown the Mthfr677C>T mouse model phenocopies humans carrying the variant and develop cerebrovascular deficits. Methods: To examine the contributions of Mthfr677C>T in the context of late-onset Alzheimer's disease (LOAD), MODEL-AD created a novel mouse strain on the C57BL/6J (B6) background that was homozygous for Mthfr677C>T, in combination with humanized Abeta;, APOEe4, and Trem2*R47H (referred to as LOAD2.Mthfr677C>T). Mice were assessed over multiple ages for disease-relevant phenotypes. Regular behavior measurements and biometric samples were collected longitudinally to 24 months of age. Blood and brain tissue were collected for transcriptomics, proteomics, human disease correlation, and neuropathology. Results: Despite lacking hallmark pathologies such as amyloid deposition and significant neuroinflammation, compared to LOAD2 controls, LOAD2.Mthfr677C>T mice showed transcriptional and proteomic signatures in the brain that relate to the cerebrovasculature, myelination, and synaptic biology, similar to those seen in human LOAD patients. Conclusions: These data further support the use of the LOAD2.Mthfr677C>T mouse model to study aspects of ADRD such as cerebrovascular compromise.

The medial temporal lobe (MTL) is crucial for episodic memory. Tau pathology is a hallmark of Alzheimer's disease (AD) and accumulates in layer-specific patterns in the MTL during aging. It is, however, unclear whether early AD pathology relates to mesoscale network signatures distinct from non-pathological aging. To address this gap, we acquired 7 Tesla submillimeter-resolution resting-state fMRI, plasma-based AD biomarkers, glial fibrillary acidic protein (GFAP) levels, APOE genotype, regional [18F]PI-2620 tau PET burden, and longitudinal episodic memory data in 75 cognitively unimpaired older adults. Older age was associated with lower perirhinal-hippocampal connectivity and lower network segregation, whereas higher plasma-based AD pathology was associated with higher perirhinal-hippocampal connectivity. Furthermore, temporal-lobe tau burden was related to altered connectivity patterns in tau-vulnerable MTL subfields and layers, dependent on GFAP levels. Retrosplenial tau burden was associated with higher hippocampal-retrosplenial connectivity consistent with tau spread along canonical hippocampal output pathways. Finally, higher connectivity within the hippocampus attenuated the negative association between temporal-lobe tau burden and memory performance but predicted unfavorable memory trajectories. Our findings show differential associations of age and AD pathology with mesoscale MTL-connectivity patterns. Importantly, increased hippocampal connectivity may support memory function in the short term while contributing to subsequent memory decline.